secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001808665-24-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio Q1 net product sales $31.9M; Rolvedon sales grow to $14.5M; guides FY $110-125M
--------------------------------------------------------------------------------

- Net product sales of $31.9M in Q1 2024 vs $41.8M in Q1 2023; net loss of $4.5M vs $3.5M loss.
- Rolvedon net sales $14.5M, up from $11.0M in Q4 2023, driven by volume growth; same-day dosing trial enrollment completed, data expected year-end.
- Indocin net sales $8.7M, down from $10.8M in Q4 2023 due to generic competition.
- Adjusted EBITDA (non-GAAP) $7.4M in Q1 2024, up from $4.5M in Q4 2023; SG&A reduced to $18.5M from $24.0M.
- FY 2024 guidance reaffirmed: net product sales $110-125M, adjusted EBITDA $20-30M; cash increased to $80.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000180866524000021/0001808665-24-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000180866524000021/asrt-20240506.htm
  HTML page:      https://secwatch.observer/filing/0001808665-24-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer